Pricing and Market Access
Reducing friction in deal making
A strong Pricing and Market Access strategy is integral to what it takes to bring a product to market and is, therefore, integral to deal making. Pricing assumptions can have an enormous impact on the valuation of an asset and are frequently a cause of misalignment with potential partners. A strong pricing narrative and a solid data generation plan to support it, is essential for success.
Expert validation of recommendations
PharmaVentures provides expert validation of recommendations for price assumptions and ensures there is a robust plan in place to achieve market access and reimbursement, consistent with the development stage of an asset. We aim to give clients certainty in pricing and market access assumptions, to increase confidence in development plans, and to strengthen their position in deal making.
Phone: +44 (0) 7931 144 097 firstname.lastname@example.org
Phone: +44 (0)7826 910 198 email@example.com
Our core methodology is a modular landscape, strategy definition, and validation technique that can be adapted to assets at any development stage:
- A comprehensive or basic pricing and market access landscape assessment from a global or sub-global perspective that will help clients understand the market and develop strategies
- Pricing, data generation, HTA and contracting strategy and assumption development that will strengthen our clients’ valuations and improve their market access narrative
- Validation through primary payer research, economic modelling and secondary quantitative validation techniques will add robustness to our clients’ assumptions and strategy
What you need, when you need it
Our pricing and market access service is tailored towards development stage and deal making and complements our other deal making capabilities.
PharmaVentures can provide clients with exactly what they need, as an addition to an existing project or as a stand-alone pricing and market access study.
Our Case Studies
The Commercialisation Strategy Challenge
An early stage biotechnology company was seeking to develop a global/regional strategy for the commercialisation of their Phase I compound to maximise the value to the company over the potential life cycle of the product.
The Pharma Deal Strategy Challenge
A mid-sized life sciences manufacturing company with new cell lines developed a novel pipeline and they sought the partnership of a global or several regional pharmaceutical companies with strong competencies in clinical development and marketing in the focus therapy areas.
Pharmaceutical Company Growth
A major pharmaceutical company was seeking mid market growth products for emerging markets. PharmaVentures was chosen because its knowledge of the global pharmaceutical market, access to proprietary data resources as well its transaction experience in effectively acquiring these on behalf of clients.
How can we help you?
Understand the payer and policy landscape in key geographies
Create and validate core pricing assumptions for valuation
Validate other market access related assumptions
Support with the development of a robust HEOR and RW data generation plan
Develop models to understand and communicate the economic case for your asset
Develop your market access strategy in language your deal partners will understand
All FCA regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited is a wholly owned subsidiary of Pharma Ventures Ltd. Past performance is not a guarantee of future performance. Information contained herein is for illustrative purposes only and should not be relied upon.
Our White Papers
The Strategic Importance of Biomarkers to the Pharmaceutical Industry
In the last few years, pharmaceutical companies have become increasingly interested in biomarkers and their incorporation into company drug development programmes and use as companion tests for targeted therapeutics.
Key Drivers of Change in the Global Pharmaceutical Manufacturing Industry
Policy-driven changes in healthcare spending and the growing significance of generic competition are acting in tandem to force pharma manufacturing companies to adopt more cost-effective manufacturing strategies resulting in an upsurge in the level of M&A activity.